Stop immediately if you experience Severe burning or stinging that doesn't fade within minutes
No significant differences in the levels of active GLP-1 were detected, but there was a trend toward higher levels of GLP-1 in the RM-LNC and SEMA-RM-LNC groups (Fig
Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)
Drug patent expiration dates and regulatory exclusivity periods are subject to change through litigation outcomes, regulatory actions, and statutory amendments
Biomarkers measuring GPx activity could predict disease onset, enabling early interventions
[39] A 2025 study in which some Parkinson's patients received exenatide found no evidence that it slowed disease progression or provided any benefit after 96 weeks
